Clear Harbor Asset Management LLC Purchases New Shares in AbbVie Inc. $ABBV

Key Points

• Clear Harbor Asset Management acquired 27,214 AbbVie shares in the second quarter, valued at approximately $6.85 million. Institutional investors and hedge funds collectively own 70.23% of AbbVie.
• AbbVie exceeded quarterly expectations with adjusted EPS of $3.65 and revenue of $16.99 billion, representing 10.2% year-over-year growth. The company issued third-quarter 2026 EPS guidance of $3.84–$3.88.
• ABBV opened at $261.50, near its 52-week high, while analysts maintained a consensus “Moderate Buy” rating with an average price target of $275.95. AbbVie also pays a quarterly dividend of $1.73 per share, yielding about 2.6%.

Clear Harbor Asset Management LLC acquired a new stake in AbbVie Inc. (NYSE:ABBV - Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 27,214 shares of the company's stock, valued at approximately $6,848,000.

Other large investors have also modified their holdings of the company. Litman Gregory Wealth Management LLC acquired a new stake in shares of AbbVie during the 4th quarter valued at about $28,000. Imprint Wealth LLC raised its holdings in AbbVie by 56.2% in the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company's stock worth $29,000 after purchasing an additional 45 shares during the period. Legacy Wealth Managment LLC ID boosted its position in AbbVie by 115.9% during the fourth quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company's stock worth $31,000 after purchasing an additional 73 shares in the last quarter. IFC & Insurance Marketing Inc. purchased a new position in AbbVie during the fourth quarter worth approximately $31,000. Finally, Abound Financial LLC acquired a new stake in AbbVie in the fourth quarter valued at approximately $32,000. Institutional investors and hedge funds own 70.23% of the company's stock.

AbbVie Price Performance

ABBV stock opened at $261.50 on Thursday. AbbVie Inc. has a 1 year low of $190.75 and a 1 year high of $267.47. The firm has a market capitalization of $462.02 billion, a PE ratio of 73.87, a price-to-earnings-growth ratio of 1.18 and a beta of 0.29. The business has a 50 day simple moving average of $254.23 and a 200-day simple moving average of $229.67.

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings data on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping analysts' consensus estimates of $3.61 by $0.04. The firm had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The firm's revenue was up 10.2% compared to the same quarter last year. During the same quarter last year, the business posted $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities research analysts expect that AbbVie Inc. will post 14.05 EPS for the current year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th were issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 2.6%. The ex-dividend date was Wednesday, July 15th. AbbVie's payout ratio is currently 195.48%.

Insider Buying and Selling at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the company's stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president owned 74,430 shares of the company's stock, valued at approximately $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 0.06% of the company's stock.

Analyst Ratings Changes

A number of analysts have recently commented on the company. BNP Paribas Exane boosted their price objective on AbbVie from $218.00 to $247.00 and gave the company a "neutral" rating in a research report on Tuesday, August 11th. Weiss Ratings upgraded AbbVie from a "hold (c)" rating to a "buy (b-)" rating in a research report on Tuesday, August 4th. Erste Group Bank raised shares of AbbVie from a "hold" rating to a "buy" rating in a research note on Wednesday, August 5th. Piper Sandler boosted their price target on shares of AbbVie from $298.00 to $303.00 and gave the stock an "overweight" rating in a report on Thursday, August 20th. Finally, HSBC restated a "buy" rating and set a $300.00 price objective on shares of AbbVie in a research report on Monday, July 6th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $275.95.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source